Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 6.1% Higher After Analyst Upgrade

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP)’s stock price rose 6.1% during trading on Friday after Royal Bank Of Canada raised their price target on the stock from $8.00 to $9.00. Royal Bank Of Canada currently has an outperform rating on the stock. Aurinia Pharmaceuticals traded as high as $9.89 and last traded at $9.81. Approximately 1,153,172 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 1,485,440 shares. The stock had previously closed at $9.25.

Separately, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently made changes to their positions in AUPH. Deutsche Bank AG grew its stake in shares of Aurinia Pharmaceuticals by 54.8% in the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company’s stock valued at $1,283,000 after buying an additional 50,575 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Aurinia Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company’s stock valued at $685,000 after acquiring an additional 2,887 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $86,000. GAMMA Investing LLC raised its position in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,744 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $9,662,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 13.5%

The business has a fifty day moving average of $8.35 and a 200-day moving average of $8.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93. The company has a market capitalization of $1.42 billion, a P/E ratio of 24.40 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 19.57%. Analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.